Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraSeptember 17, 2025
The Top 10 Things You Need to Know About ADNCA Datasets
Learn how ADNCA datasets can modernize non-compartmental analysis: enhanced compliance, automations, and faster PK data…
CertaraSeptember 11, 2025
The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape
Watch leading experts from Pfizer, Merck, Amicus, and Certara discuss how Integrated Evidence can bridge…
CertaraSeptember 3, 2025
Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH)
Learn to design drug development programs for First-in-Human (FIH) success with biomarkers, PK/PD modeling, and…
CertaraAugust 29, 2025
Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value
Discover strategies to cut risk, speed timelines, and boost investor confidence in early biotech development.
CertaraAugust 21, 2025
ToxStudio®: In silico tools to accelerate toxicology assessments
Watch to explore ToxStudio—in silico toxicology platform designed to address key preclinical safety challenges.
CertaraAugust 19, 2025
